KAT2B and lung carcinoma: Advancements in the next-generation sequencing technology have identified multiple biomarkers correlated with prognosis, immune infiltration, and therapy in lung cancer, such as adhesion molecule interacting with CXADR antigen 1 (AMICA1) (Feng et al., 2022), chromobox protein homolog 3 (CBX3) (Niu et al., 2022), and lysine acetyltransferase 2B (KAT2B) (Zhou et al., 2022).